SAB Biotherapeutics Inc. (SABSW)
0.08
-0.05 (-40.30%)
At close: Jan 14, 2025, 9:00 PM
undefined% (undefined)
| Bid | 0.08 |
| Market Cap | 738.34K |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.292 |
| PE Ratio (ttm) | 0.27 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.13 |
| Volume | 6,779 |
| Avg. Volume (20D) | 0 |
| Open | 0.13 |
| Previous Close | 0.13 |
| Day's Range | 0.08 - 0.13 |
| 52-Week Range | 0.08 - 0.13 |
| Beta | undefined |
About SABSW
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Mass...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2021
Employees 57
Stock Exchange NASDAQ
Ticker Symbol SABSW